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ABSTRACT
Background: Autophagy is a catabolic cellular process used for degradation of 
cytoplasmic organelles and preservation of cell viability. In this study we aimed to 
analyse the level of autophagy markers in benign and malignant prostate tissue and 
to evaluate the prognostic properties for patients with prostate cancer (PCa).
Results: LC3b expression was significantly upregulated in PCa, especially in 
metastatic and castration-resistant PCa samples compared to benign prostate tissue 
(p<0.001). Evaluation of expression in malignant radical prostatectomy specimens 
revealed an inverse association with preoperative serum PSA levels (p=0.02) and 
Gleason Score (p=0.07). LC3b immunoreactivity was identified as a novel predictor of 
PCa specific death after radical prostatectomy, independent of Gleason score, tumour 
stage, and surgical margin status in a multivariable cox regression analysis (hazard 
ratio 0.09, 95% confidence interval 0.01-0.69, p=0.021). A significant association 
of ATG-5 and Beclin 1 with LC3b expression could be noticed (p<0.001), but no link 
with other clincopathologic parameters was observed.
Materials and Methods: A Tissue microarray containing 468 formalin-fixed, 
paraffin-embedded prostate tissue cores was stained immunohistochemically 
for major autophagy proteins LC3b, ATG5 and Beclin 1. Immunoreactivity was 
semiquantitatively scored and correlated with pathologic and clinical parameters, 
including tumour stage, Gleason score, preoperative PSA level, biochemical recurrence 
rate and survival. The median clinical follow-up was 132 months.
Conclusion: LC3b was significantly overexpressed in malignant compared to benign 
prostate tissue. However, positive LC3b immunoreactivity in PCa, as a marker of increased 
autophagy, was independently associated with a reduced disease-specific mortality.
INTRODUCTION
When prostate cancer (PCa) is localized in the 
prostate and considered significant, the treatment of 
choice is prostatectomy or radiation [1]. In advanced 
and metastatic PCa androgen ablation is the standard of 
care to palliate symptoms and postpone cancer related 
complications [2]. However, after short-term remission, 
surviving tumour cells reappear as castration-resistant 
PCa (CRPC) and lead to death within months or few 
years [3]. Therefore, extensive efforts are made to offer 
new therapeutic options to patients with CRPC including 
development of new anti-androgens and combination 
therapies. One promising approach has been the 
pharmacological inhibition of autophagy combined with 
androgen ablation or novel antitumour agents [4].
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 19), pp: 31765-31774
Research Paper
Oncotarget31766www.impactjournals.com/oncotarget
Autophagy is a catabolic cellular mechanism 
involving degradation of unnecessary or dysfunctional 
cellular components through autophagosomes allowing 
maintenance of homeostasis and ensuring cell survival 
under stress conditions. [5] The process of autophagy is 
regulated by autophagy-related proteins (ATGs) [6]. The 
key elements necessary for autophagosome formation are 
two ubiquitin like conjugation systems: (1) the ATG12-
ATG5 and (2) the microtubule-associated protein 1 light 
chain 3 (LC3)-phosphatidylethanolamine systems [7]. 
In mammalian cells, three types of LC3 were reported; 
A, B and C, with LC3b expression being the most valid 
marker of autophagosome formation [8] and therefore one 
of the most widely used in situ techniques of autophagy 
measurement in benign and malignant tissue [9].
Whether autophagy acts as a promoter or a suppressor 
during tumorigenesis seems to be context and organ-specific. 
Improvement of the cytotoxic effect of chemotherapy drugs 
or resensitization of chemoresistent tumour cells through 
inhibition of the protective role of autophagy has been 
reported in several studies [10]. Particularly in PCa, targeting 
autophagy is a promising new therapeutic modality [11-
17]. However, the relevance of autophagy-related protein 
expression in treatment-naive PCa is largely unknown.
In the current study, we analyse the expression 
profile of the three main autophagy markers involved in 
autophagosome formation, LC3b, ATG5 and Beclin 1 
in benign prostate tissue, localized PCa, CRPC and PCa 
metastases, respectively. Autophagy marker expression 
is further correlated with clinicopathological parameters 
including biochemical recurrence free survival (BCRFS), 
overall- (OS) and disease-specific survival (DSS).
RESULTS
Descriptive analysis
Clinicopathological characteristics of the patients 
are summarized in Table 1. Men in the NADT group 
had higher mean PSA level (32.7 ±57.4 ng/ml vs. 15.6 
±19.3 ng/ml, <0.001) and more advanced tumours (pT3/4 
tumours in 56.4% vs. 32.4%, p=0.002).
A total of 420/468 (89.7%) cores could be evaluated 
for LC3b, 429/468 (91.7%) for Beclin 1 and 417/468 
(89.1%) for ATG5 immunostaining. Representative stainings 
are summarized in Figure 1. In general, positive expression 
of LC3b, Beclin 1 and ATG5 was detectable in 124 of 420 
(29.5%), 259 of 429 (55.3%) and 287 of 417 (68.8%) of 
analysable cases, respectively. Immunoreactivity for LC3b 
and Beclin 1 was low in benign prostatic tissue (BPH, 
2.5% and 24.4%, p<0.001, Figure 2). LC3b and Beclin 1 
expressions were significantly increased in primary malignant 
RP specimen (36.1% and 65.9%, p<0.001), in CRPC (34.6% 
and 62.5%, p<0.001) and in metastatic tissue (MTS, 33.3% 
and 53.1%, p<0.001). Contrary, ATG5 showed a higher 
expression in benign tissue compared to malignant tissue 
(p=0.006). NADT tissue showed a similar immunoreactivity 
for Beclin 1 and ATG5 when compared to primary RP. 
However, the expression of LC3b was significantly lower in 
these men when compared to treatment naïve tissue (11.5% 
vs. 36.1%, p<0.001). LC3b expression was higher in in local 
lymph node metastases compared to distant locations (e.g. 
liver, lung, bone; 46.7% vs. 23.8%, p=0.17).
Regarding all tissue samples, positive LC3b 
immunostaining was highly associated with positive Beclin 
1 and ATG5 immunostaining (p<0.001, Table 2). Negative 
immunoreactivity of Beclin 1 and ATG5 was associated 
in 89% and 96% of the cases with a lack of LC3b staining, 
respectively (p<0.001). However, a positive immunostaining 
for Beclin 1 and ATG5 was related to a LC3b positive staining 
in only 41% and 47% of the cases, respectively (p<0.001).
Clinicopathologic characteristics of RP patients 
were correlated with LC3b, Beclin 1 and ATG5 expression 
(Table 1). In primary PCa, patients with a negative 
immunoreactivity for LC3b had higher preoperative PSA 
levels (p=0.02) and higher Gleason scores (p=0.07). No 
associations could be found for Beclin 1 and ATG5 with 
clinicopathological parameters.
After exclusion of noninterpretable tissue samples 
(n=26) and patients who had received NADT (n=56) a total 
of 266 RP patients were considered for survival analysis. 
Postoperative PSA values were available for 235 patients 
(88.3%) with 58 not reaching a nadir of <0.1 ng/ml (e.g. 
177 included for BCRFS analysis). A total of 55 patients 
(31.1%) experienced a BCR during the follow-up period 
(30 LC3b negative, 25 LC3b positive). Clinical follow-up 
data for evaluation of the OS and DSS rate was available for 
241 patients (90.1%). Fifty patients died of any cause with 
19 due to PCa (17 LC3b negative, 2 LC3b positive).
Survival analysis
Univariate Cox regression analysis (Table 3) 
and log-rank statistics showed no association of LC3b 
(Figure 3A), Beclin 1 and ATG5 staining with BCRFS, 
in contrast to the established parameters like Gleason 
score, surgical margin status and tumour stage. However, 
positive immunoreactivity for LC3b was highly associated 
with longer OS (hazard ratio [HR] 0.48, 95% confidence 
interval [CI] 0.24-0.95, p=0.034, Figure 3B) and DSS 
(HR 0.09, CI 0.01-0.71, p=0.022, Table 4 and Figure 3C). 
The estimated 15-year DSS rate was 100% for LC3b-
positive cases and 87% for LC3b-negative tumours, 
respectively (p=0.003). In a subgroup analysis of patients 
with moderately differentiated tumours (Gleason score 
7), negative LC3b immunoreactivity was associated with 
shorter DSS times (n=145, log rank p= 0.04). Beclin 1 
and ATG5 immunostaining were not associated with 
shorter DSS.
Multivariable Cox regression analysis was 
developed for the assessment of the DSS rate. 
Characteristics of variables are shown in Table 4. Because 
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of model assumptions (noninformative censoring, 
proportional hazards), only LC3b expression, Gleason 
score, tumour stage and surgical margin status were 
considered. Positive LC3b immunoreactivity (HR 0.09, 
CI 0.01-0.69, p=0.021), higher Gleason score (HR 3.48, 
CI 1.23-9.88, p=0.019) and higher tumour stage (HR 2.23, 
CI 1.16-4.29, p=0.017) remained independent prognostic 
parameters for a PCa specific death.
DISCUSSION
This is the first study investigating expression 
levels of the established markers of autophagy LC3b, 
Beclin 1 and ATG5 and their association with the solid 
clinical endpoint of survival in a representative cohort 
of PCa patients. LC3b, a major marker of autophagy, 
was significantly upregulated in adenocarcinomas of the 
prostate, in metastatic and in CRPC. Within the group 
of patients with localized PCa, who underwent radical 
prostatectomy, the absence of LC3b immunoreactivity 
was identified as a novel predictor of PCa-specific death 
after radical prostatectomy, which was independent of the 
well-established predictive factors Gleason score, tumour 
stage, and surgical margin status.
Autophagy not only plays a central role in 
maintenance of cellular homeostasis, but also is essential 
in the process of malignant transformation [18]. The 
pro-survival and pro-death role of autophagy can differ, 
depending on several different factors such as tissue 
type, stimulating factors and cellular environment [19]. 
Accumulating evidence support the thesis, that autophagy 
is a tumour suppressor and inhibits tumour development 
by detaching damaged organelles and promoting cell 
death of cancerous cells [20]. Particularly, down-
regulation of ATG5 contributed to tumorigenesis of early-
stage cutaneous melanoma in a study by Liu et al. [21]. 
Table 1: Clinicopathological characteristic in relation to LC3b, ATG5 and Beclin 1 immunoreactivity in radical 
prostatectomy specimens (patients with neoajuvant androgen deprivation therapy were not considered)
Variable and 
Characteristics
LC3b Immunoreactivity ATG5 Immunoreactivity Beclin 1 Immunoreactivity
Negative Positive P Negative Positive P Negative Positive P
Age at diagnosis
 years (SD) 63.8 (±6) 62.9 (±6) 0.27 64.3 (±6) 63.2 (±6) 0.15 63.4 (±6) 63.6 (±6) 0.79
PSA at diagnosis
 ng/ml (SD) 16.7 (±18) 12.2 (±10) 0.02 20.3 (±31) 13.5 (±11) 0.08 13.5 (±13) 16.4 (±22) 0.28
Gleason Score (%)
 5-6 26 (51) 25 (49.0) 0.07 12 (22.6) 41 (77.4) 0.21 17 (32.1) 36 (67.9) 0.95
 7 106 (65.0) 57 (35.0) 51 (30.9) 114 (69.1) 58 (33.9) 113 (66.1)
 8-10 37 (72.5) 14 (27.5) 20 (38.5) 32 (61.5) 19 (35.2) 35 (64.8)
Tumor stage (%)
 pT2 108 (61.7) 67 (38.3) 0.34 52 (28.6) 130 (71.4) 0.21 70 (37.0) 119 (63.0) 0.13
 pT3/4 61 (67.5) 28 (31.5) 32 (36.4) 45 (63.6) 24 (27.3) 64 (72.7)
Surgical margins (%)
 negative 113 (65.3) 60 (34.7) 0.34 56 (31.3) 123 (68.7) 1.00 66 (35.9) 118 (64.1) 0.34
 positive 52 (59.1) 36 (40.9) 27 (31.0) 60 (69.0) 27 (30.0) 63 (70.0)
Nodal status (%)
 pN0 134 (66.0) 69 (34.0) 0.11 65 (31.4) 142 (68.6) 0.51 74 (34.9) 138 (65.1) 1.00
 pN1 10 (90.9)  1 (9.1)  2 (18.2)  9 (81.8)  4 (36.4)  7 (63.6)
Metastasis during follow-up* (%)
 no 107 (59.8) 72 (40.2) 0.02 57(31.0) 127 (69.0) 1.00 64 (33.5) 127 (66.5) 0.15
 yes 25 (80.6) 6 (19.4) 10 (32.3) 21 (67.7) 15 (48.4) 16 (51.6)
Continously coded variables are given with mean standard deviation (SD). Bold face reprensenting P < 0.05.
* Minimum follow-up of 5 years.
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Figure 1: Representative images of benign prostatic tissue and three different cancer tissues. Normal tissue showed negative 
LC3b (A), weak Beclin 1 (E) and strong ATG5 (I) immunoreactivity. In a radical prostatectomy case (RP) with acinar adenocarcinoma 
stronger positivity for LC3b (B) and Beclin 1 (F) was observed. In contrast, ATG5 displayed weaker expression levels (J) compared to the 
respective benign tissue. Similar staining results were found in castration resistant prostate cancer cases (CRPC; C, G and K) and a lymph 
node metastasis (D, H and L). Scale bar 100 µm.
Figure 2: A-C, Cumulative bar chart representing immunoreactivity for LC3b (A), ATG5 (B) and Beclin 1 (C) in 
different tissue types. BPH, benign prostate hyperplasia. Bars represent percentage of positive and negative cases. Table below contains 
number of patients in each group. RP, radical prostatectomy (malignant); NADT RP, neoadjuvant androgen deprivation therapy (RP 
specimen); MTS, prostate cancer metastasis; CRPC, castration-resistant prostate cancer.
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Deletions of Beclin 1 have been described in specimens 
of human breast, ovarian and prostate tumours [22, 23]. 
On the other hand, other studies reported that increased 
autophagy can support cancer development by maintaining 
the stability of intracellular environment and acts as a 
protective mechanism against apoptosis and external 
death stimuli including anti-cancer drugs [24]. Evidence 
for a role of both reduced and increased autophagy in 
cancer cells was also found in the present study; while 
higher expression of autophagy proteins were observed 
in malignant tissue, lack of autophagy proteins was 
associated with worse clinicopathological parameters and 
with an increased tumour specific mortality.
Our findings are in contrast with a recently 
published report investigating the immunohistochemical 
expression of LC3b and Beclin 1 in 96 PCa specimens 
[25]. Giatromanolaki et al. found a significant association 
of high Gleason scores and high tumour stages with high 
LC3b and Beclin 1 expression levels. However, this report 
exclusively included node-negative PCa of which 68% 
had a Gleason score of ≤6. Only 31 specimens with a 
Gleason score ≥7 and 19 with an extracapsular extension 
were evaluated compared to 214 with Gleason score ≥7 
(including 51 Gleason 8-10) and 81 with a tumour stage 
≥pT3 in the present study. Furthermore, due to the pooling 
of moderately differentiated tumours of Gleason 7 with the 
poorly differentiated of Gleason 8-10 it remains unclear, 
how many genuine high risk tumours were stained in this 
study cohort. No clinical data regarding preoperative PSA 
values, patterns of biochemical recurrences or survival 
Table 2: Correlation between cytoplasmatic immunoreactivity of LC3b, ATG5 and Beclin 1 in all tissue samples
LC3b Immunoreactivity ATG5 Immunoreactivity Beclin 1 Immunoreactivity
Negative Positive P Negative Positive P Negative Positive P
LC3b
 Negative 114 (41.5) 161 (58.5) <0.001 156 (54.7) 129 (45.3) <0.001
 Positive 13 (10.4) 112 (89.6) 7 (5.6) 117 (94.4)
ATG5
 Negative 114 (89.8) 13 (10.2) <0.001 75 (60.0) 50 (40.0) <0.001
 Positive 161 (59.0) 112 (41.0) 88 (32.0) 187 (68.0)
Beclin 1
 Negative 156 (95.7) 7 (4.3) <0.001 70 (46.0) 88 (54.0) <0.001
 Positive 129 (52.4) 117 (47.6) 50 (21.1) 187 (78.9)
Note: Bold face reprensenting P < 0.05.
Table 3: Univariable Cox regression analysis für recurrence-free survival
Variable Characteristics** Recurrence-free survival
HR 95% CI P*
Age at diagnosis years 1.01 0.97-1.06 0.527
Gleason score (grouped) 5-7 vs. 7 vs. 8-10 2.27 1.49-3.45 <0.001
Preoperative PSA level ng/mL 1.01 0.99-1.01 0.284
Surgical margin status negative vs positive 3.00 1.82-4.94 <0.001
Tumor stage (pT) pT2 vs. pT3a vs. pT3b/4 2.03 1.46-2.83 <0.001
LC3b negative vs positive 0.76 0.47-1.3 0.307
ATG5 negative vs positive 1.00 0.60-1.66 0.993
Beclin 1 negative vs positive 1.19 0.74-1.91 0.468
* Bold face reprensenting P < 0.05.
** left category used as a reference
vs, versus
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rates were available. To further validate our results, we 
analysed publicly available TCGA expression data and 
observed alterations of LC3b mRNA (MAP1LC3B) in 
70 (14%) of 498 cases. LC3b mRNA alterations (mainly 
downregulations) were associated with a significantly 
shorter disease-free survival (p=0.0219, data not shown).
Liu et al. just recently evaluated the prognostic 
impact of 5 autophagy markers on the clinical endpoint 
of BCR after radical prostatectomy and reported no 
association for LC3b in agreement with our results. Yet, 
an association of positive UNC-51-like kinase 1 (ULK1) 
reactivity with BCR was reported after a relatively short 
median follow-up of 51 months [26]. In the present 
study, no association of autophagy with BCR rates 
could be observed. However, after a median follow-up 
of over 10 years we could show that a positive LC3b 
immunoreactivity had a positive and distinct impact on 
overall and disease-specific survival. This impact remained 
significant in a multivariable analysis with a HR of 0.09 
(95% CI 0.01-0.69) for dying of PCa if the staining for 
LC3b showed an expression at the time of prostatectomy. 
LC3b immunoreactivity was an even more powerful 
predictor of PCa specific death than the well-established 
parameters Gleason score and tumour stage. However, 
the low number of prostate cancer specific deaths lead to 
a wide 95% CI in our model with a significant influence 
on the point estimator (0.09). Considering HRs of other 
biomarkers, the real HR is expected to be slightly higher 
(95% CI 0.01-0.69) without having an impact on the 
conclusions drawn from our analysis.
Patients who had received ADT prior to surgery 
were excluded from the primary analysis in order to 
minimize the confounding effect of a neoadjuvant 
treatment on protein expression. However, this population 
can be used to provide an insight on the effect of ADT on 
autophagy. Recently, several studies have investigated the 
role of autophagy as an escape mechanism of PCa exposed 
to antitumour agents, hormonal ablation and radiation 
therapy [4, 27, 28]. An inhibition of autophagy was able 
to increase the antitumour effect of these agents [12, 14]. 
Of note, inhibition of autophagy in androgen sensitive 
cell lines (e.g. LNCaP) under hormonal ablation therapy 
showed reduced cell viability, suggesting the protective 
role of autophagy in androgen withdrawal [16, 17]. We, 
therefore, expected an up-regulation of autophagy in 
hormonal naïve patients treated with androgen withdrawal 
prior to surgery. Our findings demonstrated the opposite; 
autophagy was significantly reduced in our cohort of 
patients (11.5% vs. 36.1%, p<0.001) compared to the 
control group. However, preoperative ADT was mainly 
given to patients with high-risk disease and, therefore, 
this subgroup of patients differed in its perioperative 
parameters significantly from the control group.
Based on the methods of this investigation, no 
conclusions can be drawn regarding the causal relation 
of these findings. However, our results provide a new 
insight into the role of autophagy in PCa patients and 
indicate that the regulation of autophagy in PCa depends 
on the stage of the tumour. Increased autophagy levels 
may be a sign of starvation and metabolic stress in well 
Figure 3: Kaplan–Meier curves regarding biochemical recurrence-free. (A), overall (B) and disease-specific (C) survival in 
patients with clinically localized prostate cancer and negative LC3b (LC3b -) versus positive LC3b immunoreactivity (LC3b +).
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differentiated tumours due to poorer selective advantage. 
In more aggressive tumours, cells may have activated 
other mechanisms to deal with cellular stress and nutrition 
deficiency making them independent from autophagy 
proteins. Therefore, low or no autophagy might be a sign 
of malignant cells not struggling with survival. Further 
investigations will be necessary evaluating the actual 
functional role of autophagy in different stages of PCa.
MATERIALS AND METHODS
Patients and specimen characteristics
Tissue microarrays (TMA) contained 468 
formalin-fixed, paraffin-embedded prostate tissues 
and were constructed as previously described [29]. 
Specimens were collected between 1993 and 2007 from 
the Institute of Surgical Pathology, University Hospital 
of Zurich, Switzerland. The TMA included a series 
of 348 consecutive (non-selected) malignant radical 
prostatectomy (RP) specimens, 29 CRPC samples, 18 
lymph node metastases, 28 distant metastases (bone, lung, 
urinary bladder), and 45 benign prostatic hyperplasia 
samples. A neoadjuvant androgen deprivation therapy 
(NADT) had been established preoperatively in 56 men 
with primary PCa. Haematoxylin and eosin–stained slides 
of all specimens were re-evaluated by two experienced 
pathologists (P.J.W., H.M.) to identify representative 
areas. Tumour stage and Gleason score of the Zurich 
cohort were assigned according to the International 
Union Against Cancer and World Health Organization/
International Society of Urological Pathology criteria [30]. 
In total, clinical follow-up data were available for 317 of 
348 prostatectomy patients (91.1%). After RP, follow-up 
of patients was conducted by periodic measurement of the 
serum PSA. Median follow-up was 132 months (range 
1–252). The study was approved by the local scientific 
ethics committees (KEK-ZH-No.2008-0025).
Immunohistochemical assay
Consecutive 3-μM sections were cut from the 
TMA tissue blocks. The expression of Beclin 1, ATG5 
and LC3b was analysed immunohistochemically using 
the following primary antibodies: anti-Beclin 1 (rabbit 
polyclonal; Novus Biologicals, LLC; no. NB110-87318, 
dilution 1:200), anti-ATG5 (rabbit polyclonal; Sigma-
Aldrich Corporation; no. A0731, dilution 1:1000) and 
anti-LC3b (rabbit polyclonal; Abcam plc; no. ab48394, 
dilution 1:200). Beclin 1 and ATG5 stainings were 
detected by Discovery UltraMap anti-rabbit IgG in 
combination with ChromoMap DAB Detection Kit 
(Ventana Medical Systems, Inc.) and LC3b by UltraView 
Universal DAB Detection Kit (Ventana). After antigen 
Table 4: Uni- (A) and multivariable (B) Cox regression analysis for tumor-specific survival
A. Univariable
Variable Characteristics** Prostate cancer-specific survival
HR 95% CI P*
Age at diagnosis Years 1.06 0.97-1.16 0.177
Gleason score (grouped) 5-6 vs. 7 vs. 8-10 4.70 2.16-10.23 <0.001
Preoperative PSA level ng/mL 1.01 0.99-1.02 0.171
Surgical margin status negative vs. positive 2.35 1.0-5.54 0.050
Tumor stage (pT) pT2 vs. pT3a vs. pT3b/4 3.15 1.90-5.2 <0.001
LC3b negative vs. positive 0.09 0.01-0.71 0.022
ATG5 negative vs. positive 0.60 0.24-1.53 0.287
Beclin 1 negative vs. positive 1.05 0.41-2.6 0.924
B. Multivariable
Gleason score (grouped) 5-6 vs. 7 vs. 8-10 3.48 1.23-9.88 0.019
Surgical margin status negative vs. positive 1.34 0.48-3.69 0.576
Tumor stage (pT) pT2 vs. pT3a vs. pT3b/4 2.23 1.16-4.29 0.017
LC3b negative vs. positive 0.09 0.01-0.69 0.021
* Bold face reprensenting P < 0.05.
** left category used as a reference
vs, versus
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retrieval (microwave oven for 10 minutes at 250 W) 
immunohistochemistry for Beclin 1 and ATG5 was 
carried out in a Discovery Ultra stainer (Ventana) and for 
LC3b in a Benchmark Ultra stainer (Ventana) according 
to the manufacturer’s instructions. Normal prostatic and 
testicular parenchyma was chosen as positive control. 
For negative controls, the primary antibody was omitted. 
The specificity of the commercial antibodies has been 
thoroughly validated in former studies [31-34].
Antibody specificity test
The specificity of the anti-LC3b (rabbit polyclonal; 
Abcam plc; no. ab48394, dilution 1:200) antibody was 
tested using LnCaP prostate cancer cells (American Type 
Culture Collection, Manassas, VA). LnCaP cells were 
cultured in the presence of pharmacological modulator 
of autophagy, 5 mM 3-MA (Sigma-Aldrich, Buchs, 
Switzerland), an inhibitor commonly used to block 
autophagy [35] and 2 µM rapamycin (LuBioScience, 
Luzern, Switzerland) an inducer of autophagy for 7 days 
on the slide flasks (Nunc flasks, cat: 170920). Cells were 
immunostained with anti-LC3b (1:200) for 24h at 4°C. 
The slides were incubated with secondary antibody Cy3-
conjugated sheep anti-rabbit antibody (Sigma, 1:200) at 
room temperature for 1 h. The slides were counter-stained 
with DAPI (4’,6-diamidino-2-phenylindole, Sigma, 
1:200) and analysed with a Leica fluorescence microscope 
(40x). The specificity of the anti-LC3b antibody could be 
confirmed by detecting no staining in the negative control, 
a minimal staining in cells inhibited by 3MA, a modest 
staining in untreated cells (basal autophagy level) and the 
typical LC3b punctuation in cells induced by rapamycin 
(Supplementary Figure 1).
Immunohistochemical readout
One surgical pathologist (N.J.R.) and one urologist 
experienced in TMA readouts (A.M.) performed a blinded 
evaluation of the slides without knowledge of clinical data. 
In case of a discrepancy the core was assessed by a senior 
pathologist (P.J.W.). Causes of noninterpretable results 
included lack of target tissue, presence of necrosis, or crush 
artefact. Since autophagy proteins showed a homogeneous 
expression pattern, staining intensity (exclusively 
cytoplasmic staining pattern was evaluated) was assigned 
using a semiquantitive, four-tired score: negative (0), 
weak (1+), moderate (2+) or strong (3+). In cases with 
heterogeneity, the predominant staining intensity (>80%) 
was counted. Searching for cut-offs in an unbiased way 
is a major problem in immunohistochemical studies 
dealing with a continuous readout. The median LC3b 
immunoreactivity in prostatectomy cases with malignant 
tissue (weak) was chosen as cut-off. Accordingly, positive 
LC3b, ATG5 and Beclin 1 immunoreactivity was defined 
as moderate or strong staining of target cells.
Statistical analyses
SPSS version 22.0 (IBM Corporation, Armonk, 
NY, USA) was used for statistical analyses. To study 
statistical associations between clinicopathologic and 
immunohistochemical data, contingency table analysis 
with 2-sided Fisher’s exact tests were used for categorical 
and the student t-test for continuous variables. Descriptive 
statistical analyses for patients who had received any 
hormonal manipulation preoperatively (NADT) were 
performed separately. Only patients who were treated 
by radical prostatectomy were considered for survival 
analysis. The outcome measures were biochemical 
recurrence-free survival (BCRFS), overall survival 
(OS) and disease-specific survival (DSS). Biochemical 
recurrence (BCR) was defined as PSA value ≥0.1 ng/
mL with subsequent confirmation after reaching the PSA 
nadir of 0.1 ng/ml postoperatively. Patients not reaching 
this nadir threshold postoperatively were excluded from 
BCRFS analysis. Univariate Cox regression analysis 
was performed for BCRFS and DSS. Investigated 
variables were age, Gleason score, preoperative PSA 
level, pathologic tumour stage, surgical margin status, 
immunoreactivity for LC3b, ATG5 and Beclin 1. A 
stepwise multivariable Cox regression model was adjusted, 
testing the independent prognostic relevance of LC3b 
immunoreactivity for DSS. BCRFS, OS and DSS curves 
were calculated using the Kaplan–Meier method with 
significance evaluated by 2-sided log-rank statistics. All 
p-values <0.05 were considered statistically significant.
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